Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

Pharming « Terug naar discussie overzicht

CHMP adopts positive opinion to include self-administration for RUCONEST®

36 Posts, Pagina: 1 2 » | Laatste

Omlaag ↓

[verwijderd] 11 november 2016 07:11

CHMP adopts positive opinion to include self-administration for RUCONEST®
• Home-administration recommended to be included in label for use of RUCONEST®, with a new custom-designed administration kit
• Final decision from European Commission anticipated in January 2017
• Administration kits expected to be available in EU markets soon thereafter
• EU approval of self-administration is further to US approval received in 2014
Leiden, The Netherlands, 11 November 2016: Pharming Group N.V. (the “Company”) (EURONEXT: PHARM) today announced that following evaluation of a dossier submitted by the Company earlier this year, the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has adopted a positive opinion recommending an extension to the terms of the marketing authorisation for RUCONEST® to the European Commission. This recommendation will allow self-administration of RUCONEST® for acute hereditary angioedema (HAE) attacks by adolescents and adults with a new custom-designed administration kit. Following normal timelines after the adoption of the positive opinion by CHMP, the final decision from the European Committee is expected in January 2017. It is expected that the kits will become available for use in the various EU markets soon thereafter.

jurpsy 11 november 2016 07:19

Eerst de Ige test die vervalt , nu de S.A.K......
De voorschrijvers hebben geen belemmeringen meer . ..
De patiënten krijgen/hebben Ruconest elk moment binnen handbereik .

Top !

[verwijderd] 11 november 2016 07:22

CHMP adopts positive opinion to include self-administration for RUCONEST®

Home-administration recommended to be included in label for use of RUCONEST®, with a new custom-designed administration kit
Final decision from European Commission anticipated in January 2017
Administration kits expected to be available in EU markets soon thereafter
EU approval of self-administration is further to US approval received in 2014
Leiden, The Netherlands, 11 November 2016: Pharming Group N.V. (the “Company”) (EURONEXT: PHARM) today announced that following evaluation of a dossier submitted by the Company earlier this year, the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine Agency (EMA), has adopted a positive opinion recommending an extension to the terms of the marketing authorisation for RUCONEST® to the European Commission. This recommendation will allow self-administration of RUCONEST® for acute hereditary angioedema (HAE) attacks by adolescents and adults with a new custom-designed administration kit. Following normal timelines after the adoption of the positive opinion by CHMP, the final decision from the European Committee is expected in January 2017. It is expected that the kits will become available for use in the various EU markets soon thereafter.

HAE is a rare disease caused by a deficiency of the C1 esterase inhibitor protein and is characterized by spontaneous and recurrent episodes of swelling (edema attacks) of the skin in different parts of the body, as well as in the airways and internal organs. Edema of the throat, nose or tongue is particularly dangerous and potentially life-threatening and can lead to obstruction of the airway passages.

If the CHMP opinion is adopted by the European Commission and the approval of the associated educational materials is granted by national authorities, the new RUCONEST® self-administration kit will become available for patients, making dealing with an attack simpler. These custom-designed self-administration kits have already been favorably tested by volunteers. These kits are intended to enable patients or their caregivers to treat their HAE attacks in the comfort and privacy of their own homes or at any other place they choose, without the necessity of a healthcare professional (HCP) being present.

Prof. Bruno Giannetti, MD, PhD, Pharming’s COO, commented:

“This EU label change proposal is yet another testament to RUCONEST®’s well-established and favorable safety profile. Over 25,000 post-approval vials of RUCONEST® to treat HAE attacks have now been prescribed, making it a convenient, safe and effective way to stop these attacks. Following approval of this administration kit, it will be as convenient to use RUCONEST® in the EU as it already is in the US.”

Self-administration (at home or without a HCP present) was granted immediately on approval in the US as a result of more safety data being available at the time of the Biologics License Application (BLA) and subsequent Food and Drug Administration (FDA) approved label in July 2014.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

Please see Prescribing Information for RUCONEST® as applicable for various jurisdictions.

EMA:

www.ema.europa.eu/docs/en_GB/document...

FDA:

www.fda.gov/downloads/BiologicsBloodV...

About HAE

Hereditary Angioedema (HAE) is a rare genetic disorder. The condition is caused by a deficiency of the C1 esterase inhibitor protein, which is normally present in blood and helps control inflammation (swelling) and parts of the immune system. Because defective C1-Inhibitor does not adequately perform its regulatory function, a biochemical imbalance can occur and produce unwanted peptides that induce the capillaries to release fluids into surrounding tissue, thereby causing swelling or edema.

HAE is characterized by spontaneous and recurrent episodes of swelling (edema attacks) of the skin in different parts of the body, as well as in the airways and internal organs. Edema of the skin usually affects the extremities, the face, and the genitals. Patients suffering from this kind of edema often withdraw from their social lives because of the disfiguration, discomfort and pain these symptoms may cause. Almost all HAE patients suffer from bouts of severe abdominal pain, nausea, vomiting and diarrhea caused by swelling of the intestinal wall.

Edema of the throat, nose or tongue is particularly dangerous and potentially life-threatening and can lead to obstruction of the airway passages. Although there is currently no known cure for HAE, it is possible to treat the symptoms associated with angioedema attacks. HAE affects about 1 in 10,000 to 1 in 50,000 people worldwide. Experts believe that a lot of patients are still seeking the right diagnosis: although HAE is (in principle) easy to diagnose, it is frequently identified very late or not discovered at all. The reason HAE is often misdiagnosed is because the symptoms are similar to those of many other common conditions such as allergies or appendicitis. By the time it is diagnosed correctly, the patient has often been through a long-lasting ordeal.

About RUCONEST®

RUCONEST® (recombinant C1 esterase inhibitor) is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks.

RUCONEST contains C1 esterase inhibitor at 50 IU/kg. When administered at the onset of HAE attack symptoms at the recommended dose, RUCONEST may help to return a patient’s C1 esterase inhibitor levels to normal range and relieve the symptoms of an HAE attack with a low recurrence of symptoms within 24 hours.

RUCONEST is the only recombinant C1 esterase inhibitor approved by the U.S. Food and Drug Administration (FDA) and was approved in July 2014.

Recently RUCONEST® demonstrated very positive data for prophylaxis (prevention) in patients with HAE. If approved for this indication, RUCONEST® will have access to this additional market. RUCONEST® therefore, has the potential to be the only recombinant C1 esterase inhibitor product approved to target both the acute market (worth approximately $845 million) and the HAE prophylaxis market (separately worth approximately $700 million).

About Pharming Group N.V.

Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US and rest of the world. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

[verwijderd] 11 november 2016 07:40

These custom-designed self-administration kits have already been FAVORABLY- tested by volunteers.

favorably gunstig
favorably goedgunstig

[verwijderd] 11 november 2016 07:45

Er is het afgelopen jaar heel veel geïnvesteerd in een extra grote voorraad van Ruconest.
Pharming is er klaar voor.
Zoals hier vaak gezegd : de kosten gaan voor de baat uit.
Goed gezien van de directie.

[verwijderd] 11 november 2016 07:45

Geen arts of specialist meer nodig dus. Wel zo praktisch.

Daarnaast een product hebben zonder risico's die een plasmaproduct wel heeft.
En een product hebben..... dat er gewoon is ( geen enkel leveringsprobleem)

Tsja... lastige keuze

:-)

[verwijderd] 11 november 2016 08:25

Dit bericht gaat snel de wereld rond nu,en ik kan het weten :-)

GEEN BRON :-)

[verwijderd] 11 november 2016 08:28

finance.yahoo.com/news/chmp-adopts-po...

Heel snel!

:-)

Franske53 11 november 2016 08:32

Na lang wachten komt het goed met Pharming !! de aanhouder wint

[verwijderd] 11 november 2016 08:34

quote:
weltevree schreef op 11 november 2016 08:25:
Dit bericht gaat snel de wereld rond nu,en ik kan het weten :-)

GEEN BRON :-)

Zeker Weltevree.
Alle HAE-verenigingen plaatsen dit nieuws op hun site in hun nieuwsberichten.

Betrokken artsen wereldwijd lezen dit nieuws ook en volgden bovendien de twee conferenties in Amerika van deze week waar Ruconest werd besproken door professoren die aan de fase II studie hebben meegewerkt.

Prima allemaal voor de bekendheid van Ruconest.

[verwijderd] 11 november 2016 08:42

Ben benieuwd of en zo ja wanneer KBC op dit nieuws reageren zal.

Rob 74 11 november 2016 08:47

quote:
franske 53 schreef op 11 november 2016 08:32:
Na lang wachten komt het goed met Pharming !! de aanhouder wint

eindelijk weer eens een positieve dag voor de aandeelhouder van dit aandeel dat gefundeerd is!

[verwijderd] 11 november 2016 08:49

Niet elke 11e van de 11e is altijd maar hetzelfde ,soms is er een hit, dat is vandaag :
a new custom-designed administration kit

Proficiat Pharming

CW1884 11 november 2016 08:50

quote:
marlanki schreef op 11 november 2016 08:42:
Ben benieuwd of en zo ja wanneer KBC op dit nieuws reageren zal.

Ik vraag me af of KBC überhaupt Pharming nog volgt, nu dhr. de Kerpel niet meer werkzaam is voor KBC.

Cor S 11 november 2016 08:54

Vandaag inde fd

fd.nl/ondernemen/1175194/leveringspro...

[verwijderd] 11 november 2016 08:58

Nu nog profylactisch er over heen :-)

[verwijderd] 11 november 2016 08:58

quote:
weltevree schreef op 11 november 2016 08:49:
Niet elke 11e van de 11e is altijd maar hetzelfde ,soms is er een hit, dat is vandaag :
a new custom-designed administration kit

Proficiat Pharming

hee dit rijmt:)

[verwijderd] 11 november 2016 08:59

i.o. 0,228

[verwijderd] 11 november 2016 09:17

Zo eerst even de handelaartjes laten uitrazen en dan maar weer eens kijken of er leuke hapjes te verkrijgen zijn :-)

[verwijderd] 11 november 2016 09:18

Het gap van vanochtend moet zeker nog even worden gedicht, alvorens weer verder te stijgen. Hoop van niet natuurlijk met die positieve berichten, en nog een aantal in het verschiet.

36 Posts, Pagina: 1 2 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	23 apr 2024 11:53
Koers	0,918
Verschil	+0,018 (+1,94%)
Hoog	0,923
Laag	0,905
Volume	1.654.388
Volume gemiddeld	6.940.923
Volume gisteren	6.570.354

Pharming nieuws

19 apr	Pharming lost voor 123 miljoen euro a...
18 apr	Pharming rondt plaatsing obligaties af
18 apr	Pharming vervangt converteerbare lening
08 apr	Pharming rondt rekrutering voor klini...
14 mrt	CEO: Pharming haalt omzet uit steeds ...
14 mrt	Lichte plus voor AEX voorzien; zullen...
14 mrt	Pharming rekent ook voor 2024 op dubb...
13 mrt	Slotcall: Twijfel slaat toe bij chipp...
11 mrt	Beursblik: hogere jaaromzet Pharming ...
11 mrt	AEX gaat opnieuw rode opening tegemoe...	1

Meer ››